ICICI Securities's research report on Star Health and Allied Insurance
We believe Star Health (Star) is on a steady earnings growth trajectory driven by better incremental balance between volume growth and profitability, as witnessed in its H1FY26 result (13.1% YoY growth in GEP, while IFRS PAT grew 20.9% YoY). We expect various initiatives undertaken in FY25 to yield results in earnings from H2FY26. This may be supported by: 1) Strong retail fresh business growth (24% YoY growth in H1FY26 and 50% in Oct’25). 2) Reducing group exposure (GWP contribution fell from 9% in Q2FY25 to 5% in Q2FY26). Star experienced a rise in group segment’s loss ratio from 78% in Q1FY25 to 85.1% in Q1FY26. This improved in H1FY26 to 82.1% (vs. 85.9% in H1FY25). 3) Benefit of repricing undertaken in 60-65% of portfolio in mid-FY25 and calibrated annual repricing strategy. 4) Higher equity AUM with mix increasing from 6.7% in Mar’24 to 15% in Mar’25 and 18% in Sep’25. 5) Several digital initiatives could improve efficiency with EOM at 32.3% in Q2FY26 (calculated).
Outlook
We maintain BUY on Star with a revised TP of INR 570 (earlier INR 512), based on 20x FY28E EPS of INR 28.4 (earlier 25x on FY27E EPS of INR 20.5) under IFRS. Key risks: Higher competitive intensity or claim denting profitability apart from risk on margins from GST cut.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.